AFT Pharmaceuticals Limited (AFT.NZ)
NZSE · NZD · Healthcare · Drug Manufacturers - Specialty & Generic
NZ$4.63 (-0.22%) as of
Key statistics
- Market cap
- 485.57M
- P/E (TTM)
- 33.07
- Forward P/E
- 19.57
- EPS (TTM)
- 0.1400
- Dividend yield
- 0.54%
- 52-week range
- 3.0000 – 4.8500
- Beta
- 0.47
- Revenue (TTM)
- 254.7M
- Profit margin
- 5.78%
- Analyst target
- NZ$4.85
- Volume
- 7.70k
About AFT Pharmaceuticals Limited
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a research and development collaboration with Hyloris Pharmaceuticals SA for the development of the Maxigesic IV product. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Auckland, New Zealand
- Employees
- 126
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.
Related stocks
- EROAD Limited Ordinary Shares (ERD.NZ)
- Smart S&P/NZX NZ Government Bon (NGB.NZ)
- Pacific Edge Limited Ordinary S (PEB.NZ)
- Smart Global ESG ETF Units (ESG.NZ)
- Bremworth Limited Ordinary Shar (BRW.NZ)
- AIA 2/11/2029 6.22% Auckland In (AIA270.NZ)
- Smart US Large Value ETF Units (USV.NZ)
- Taiko Critical Minerals Limited (TCM.NZ)